Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers

被引：1
|
作者：
Manyara, Anthony Muchai [1 ]
Ciani, Oriana [2 ]
Taylor, Rod S. [1 ,3 ]
机构：
[1] Univ Glasgow, MRC CSO Social & Publ Hlth Sci Unit, Berkeley Sq,99 Berkeley St, Glasgow G3 7HR, Lanark, Scotland
[2] SDA Bocconi Sch Management, Milan, Italy
[3] Univ Glasgow, Roberston Ctr Biostat, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland
来源：
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS | 2022年 / 8卷 / 01期
基金：
英国医学研究理事会;
关键词：
D O I：
10.1002/trc2.12344
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Biomarkers and surrogate endpoints: How and when might they impact drug development?
    Lathia, CD
    DISEASE MARKERS, 2002, 18 (02) : 83 - 90
  • [32] Moving Beyond Surrogate Endpoints in Cell Therapy Trials for Heart Disease
    Malliaras, Konstantinos
    Marban, Eduardo
    STEM CELLS TRANSLATIONAL MEDICINE, 2014, 3 (01) : 2 - 6
  • [33] Exercise training in heart failure: time to go beyond surrogate endpoints
    Dickstein, K
    EUROPEAN JOURNAL OF HEART FAILURE, 2000, 2 (01) : 5 - 6
  • [34] Surrogate endpoints for clinical trials in non-alcoholic steatohepatitis Reply
    Sanyal, Arun J.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (08): : 550 - 551
  • [35] Cardiac magnetic resonance biomarkers as surrogate endpoints in cardiovascular trials for myocardial diseases
    Benz, Dominik C.
    Grani, Christoph
    Antiochos, Panagiotis
    Heydari, Bobak
    Gissler, Mark Colin
    Ge, Yin
    Cuddy, Sarah A. M.
    Dorbala, Sharmila
    Kwong, Raymond Y.
    EUROPEAN HEART JOURNAL, 2023, 44 (45) : 4738 - 4747
  • [36] Biomarkers as surrogate endpoints in clinical trials for HIV/AIDS: a model for other diseases?
    Mildvan, D
    BIOMARKERS AND SURROGATE ENDPOINTS: CLINICAL RESEARCH AND APPLICATIONS, 2000, 1205 : 13 - 17
  • [37] Use of Meta-Analysis for the Validation of Surrogate Endpoints and Biomarkers in Cancer Trials
    Buyse, Marc
    CANCER JOURNAL, 2009, 15 (05): : 421 - 425
  • [38] Implications of the Institute of Medicine Report: Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
    Wagner, J. A.
    Ball, J. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (01) : 12 - 15
  • [39] Biomarkers for Early Detection and as Surrogate Endpoints in Cancer Prevention Trials: Issues and Opportunities
    Dunn, Barbara K.
    Jegalian, Karin
    Greenwald, Peter
    CLINICAL CANCER PREVENTION, 2011, 188 : 21 - 47
  • [40] A cost-benefit approach to the regulation, qualification and acceptance of biomarkers and surrogate endpoints
    Williams, S. A.
    Slavin, D. E.
    Wagner, J. A.
    Webster, C. J.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 480 - 480
12345